(Bloomberg) — Shares of Samsung Electronics Co. are on track to underperform those of its smaller memory-chip rival SK Hynix Inc. by the most in a decade as investors bet the latter will be the winner in artificial intelligence.
Most Read from Bloomberg
SK Hynix has surged 67% this year thanks to its deal to supply premium high-bandwidth memory chips to Nvidia Corp., trouncing Samsung, which is up 24% as it struggles to get its HBM offering off the ground. That gap may widen further judging by options data, which show the put-to-call ratio on Samsung more than double that of SK Hynix.
The AI battle is pitched against the backdrop of weak global demand for the companies’ traditional memory products. That’s due in large part to smartphones, which are mired in what could be the worst industrywide slump in over a decade, hurting another key source of revenue for Samsung.
Chips remain hot overall thanks to the surge in demand for products needed to power generative AI services like ChatGPT. The Philadelphia Semiconductor Index up 31% this year, outpacing gains in nearly any benchmark you can think of.
Samsung has another way to tap this growth, as it also provides contract chip-manufacturing services. But it’s missing out here as well because Taiwan Semiconductor Manufacturing Co. dominates foundry business, producing the lion’s share of AI processors designed by Nvidia and others.
So after years of leading the memory industry, Samsung is now seen needing to play catchup in HBM, an advanced technology optimized to work with AI accelerators. HBM features a stack of DRAM that sits on top of a processor instead of being housed in a separate memory module, enabling faster data transfer.
SK Hynix — more of a “pure-play” memory maker than its diversified peer — was able to get a jump on the latest generation of the chip, winning Nvidia as a customer for its HBM3. Samsung reportedly had trouble finalizing a contract with the US AI giant for its offering, though it has developed a new HBM3E chip and said it plans to introduce an HBM4 by 2025.
“This is a really unfamiliar scene,” with Samsung falling behind SK Hynix in HBM development, said Yoon Joonwon, a fund manager at DS Asset Management Co. “Everyone is focused on AI as that’s the only area where we see strong demand.”
Yoon sees securing a client such as Nvidia or Advanced Micro Devices Inc. as key for Samsung’s share price. Other observers point to yield, the amount of good chips it can produce from each batch of material, as the main thing for investors to monitor.
Such points will be closely watched for by analysts in the companies’ earnings reports later this month. Samsung’s recently released preliminary results showed a more modest slide in quarterly profit. Both companies have a similar amount of buy ratings and no sells, according to Bloomberg-compiled data. However, consensus price targets for Samsung indicate a gain more than 30% from its current level over the next 12 months, compared with around 20% for SK Hynix.
For market watchers like Lee Seung-Woo, an analyst at Eugene Investment & Securities, potential for change in AI leadership is possible further down the road, but it won’t be quick.
“Samsung won’t be staying behind forever,” said Lee, who rates the company a buy. “Samsung will likely start shipping the next version of HBM3 within this year, which will reduce the gap to about four to five months. SK Hynix will continue to maintain its lead, but Samsung will be able to reduce the gap next year.”
Top Tech Stories
Key iPhone assembler Hon Hai Precision Industry Co. said it will collaborate with Chinese authorities on unspecified probes, following a report that officials are conducting tax audits and reviewing land use by parent Foxconn Technology Group Co.
Kioxia Holdings Corp. has approached Japan Investment Corp. about making a capital infusion to support its merger with Western Digital Corp. and strengthen the combined company’s financial base, according to people familiar with the matter.
Roche Holding AG is turning to artificial intelligence to find patients who can benefit from its lung cancer drug Alecensa. Roche will use an AI collaboration with Israeli tech company Medial EarlySign Ltd. to help doctors determine when to use CT scans in order to help find tumors before they spread.
Most Read from Bloomberg Businessweek
©2023 Bloomberg L.P.
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel